{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T22:14:23Z","timestamp":1795126463093,"version":"4.10.3"},"reference-count":22,"publisher":"American Chemical Society (ACS)","issue":"22","license":[{"start":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T00:00:00Z","timestamp":1762732800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T00:00:00Z","timestamp":1762732800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T00:00:00Z","timestamp":1762732800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-045"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82473780"],"award-info":[{"award-number":["82473780"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/na","name":"Jiangsu Funding Program for Excellent Postdoctoral Talent","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/na","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,27]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Current clinical proteasome inhibitors suffer from nonselective pan-inhibition, leading to severe toxicity. Selective immunoproteasome inhibition offers a safer therapeutic strategy for autoimmune diseases. However, the inadequate LMP7\/\u03b25 selectivity of existing immunoproteasome inhibitors still lead to potential clinical side effects. To overcome this limitation, we designed and synthesized a series of novel immunoproteasome inhibitors featuring a bridged ring. The optimal compound A33 exhibited potent LMP7 inhibitory activity with &amp;gt;100-fold selectivity over \u03b25 at the cellular level, along with ancillary activity against LMP2\/MECL-1. Remarkably, A33 showed excellent anti-inflammatory effects in a mouse model of arthritis, and a favorable safety profile in toxicological studies, with reduced hepatotoxicity and hematotoxicity. Critically, we established a direct correlation between high LMP7\/\u03b25 selectivity and diminished systemic toxicity. In addition, A33 had favorable pharmacokinetic characteristics both in vitro and in vivo. These attractive drug-like properties establish A33 as a promising preclinical candidate compound with optimized selectivity and improved safety profile that merit further investigation.<\/jats:p>","DOI":"10.1021\/acs.jmedchem.5c02583","type":"journal-article","created":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T06:20:09Z","timestamp":1762755609000},"page":"24579-24602","source":"Crossref","is-referenced-by-count":1,"title":["Discovery of\nNovel Potent and Safe Immunoproteasome\nInhibitors with Bridged Ring for Anti-Inflammatory Therapy"],"prefix":"10.1021","volume":"68","author":[{"given":"Jian","family":"Wu","sequence":"first","affiliation":[{"name":"China Pharmaceutical University , , ,","place":["Nanjing, P. R. China, 211198"]},{"name":"Nanjing Chia-Tai Tianqing Pharmaceutical Co., Ltd. , , ,","place":["Nanjing, P. R. China, 210046"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-9315-4729","authenticated-orcid":true,"given":"Shi","family":"Cai","sequence":"additional","affiliation":[{"name":"Nanjing Chia-Tai Tianqing Pharmaceutical Co., Ltd. , , ,","place":["Nanjing, P. R. China, 210046"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jincai","family":"Su","sequence":"additional","affiliation":[{"name":"Nanjing Chia-Tai Tianqing Pharmaceutical Co., Ltd. , , ,","place":["Nanjing, P. R. China, 210046"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojun","family":"Ji","sequence":"additional","affiliation":[{"name":"Nanjing Chia-Tai Tianqing Pharmaceutical Co., Ltd. , , ,","place":["Nanjing, P. R. China, 210046"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiuhua","family":"Zhou","sequence":"additional","affiliation":[{"name":"Nanjing Chia-Tai Tianqing Pharmaceutical Co., Ltd. , , ,","place":["Nanjing, P. R. China, 210046"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zehong","family":"Chen","sequence":"additional","affiliation":[{"name":"China Pharmaceutical University , , ,","place":["Nanjing, P. R. China, 210009"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiqing","family":"Fan","sequence":"additional","affiliation":[{"name":"China Pharmaceutical University , , ,","place":["Nanjing, P. R. China, 210009"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuefei","family":"Li","sequence":"additional","affiliation":[{"name":"Nanjing Chia-Tai Tianqing Pharmaceutical Co., Ltd. , , ,","place":["Nanjing, P. R. China, 210046"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiang","family":"Liu","sequence":"additional","affiliation":[{"name":"Nanjing Chia-Tai Tianqing Pharmaceutical Co., Ltd. , , ,","place":["Nanjing, P. R. China, 210046"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanting","family":"Dong","sequence":"additional","affiliation":[{"name":"Nanjing Chia-Tai Tianqing Pharmaceutical Co., Ltd. , , ,","place":["Nanjing, P. R. China, 210046"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changyou","family":"Ma","sequence":"additional","affiliation":[{"name":"Nanjing Chia-Tai Tianqing Pharmaceutical Co., Ltd. , , ,","place":["Nanjing, P. R. China, 210046"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Xu","sequence":"additional","affiliation":[{"name":"Nanjing Chia-Tai Tianqing Pharmaceutical Co., Ltd. , , ,","place":["Nanjing, P. R. China, 210046"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3827-0992","authenticated-orcid":true,"given":"Hai","family":"Qian","sequence":"additional","affiliation":[{"name":"China Pharmaceutical University , , ,","place":["Nanjing, P. R. China, 211198"]},{"name":"China Pharmaceutical University , , ,","place":["Nanjing, P. R. China, 210009"]},{"name":"China Pharmaceutical University , , ,","place":["Nanjing, P. R. China, 210009"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"316","published-online":{"date-parts":[[2025,11,10]]},"reference":[{"key":"2026073102053715000_cit1","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-019-0141-9","article-title":"Lupus nephritis","volume":"6","author":"Anders","year":"2020","journal-title":"Nat. Rev. Dis. Primers"},{"key":"2026073102053715000_cit2","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1007\/s00281-013-0413-5","article-title":"Immunopathology of lupus nephritis","volume":"36","author":"Anders","year":"2014","journal-title":"Semin. Immunopathol."},{"key":"2026073102053715000_cit3","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1097\/01.mnh.0000444816.57378.21","article-title":"Lupus nephritis:\nupdate on mechanisms\nof systemic autoimmunity and kidney immunopathology","volume":"23","author":"Lorenz","year":"2014","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"key":"2026073102053715000_cit4","doi-asserted-by":"publisher","first-page":"i71","DOI":"10.1093\/ndt\/gfw300","article-title":"Biomarkers of lupus\nnephritis histology and flare:\ndeciphering the relevant amidst the noise","volume":"32","author":"Birmingham","year":"2017","journal-title":"Nephrol.,\nDial., Transplant."},{"key":"2026073102053715000_cit5","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25168981","article-title":"Lupus Nephritis\nfrom Pathogenesis to New Therapies: An Update","volume":"25","author":"Roveta","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"2026073102053715000_cit6","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1038\/nature10774","article-title":"Complete subunit architecture\nof the proteasome regulatory\nparticle","volume":"482","author":"Lander","year":"2012","journal-title":"Nature"},{"key":"2026073102053715000_cit7","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1007\/BF02705243","article-title":"The ubiquitin-proteasome\nsystem","volume":"31","author":"Nandi","year":"2006","journal-title":"J. Biosci."},{"key":"2026073102053715000_cit8","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1038\/nm.1978","article-title":"A selective\ninhibitor of the immunoproteasome subunit LMP7 blocks cytokine production\nand attenuates progression of experimental arthritis","volume":"15","author":"Muchamuel","year":"2009","journal-title":"Nat. Med."},{"key":"2026073102053715000_cit9","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2024.123125","article-title":"Bortezomib in cancer therapy: Mechanisms, side effects,\nand future proteasome inhibitors","volume":"358","author":"Sogbein","year":"2024","journal-title":"Life Sci."},{"key":"2026073102053715000_cit10","doi-asserted-by":"publisher","first-page":"2361","DOI":"10.1016\/S0140-6736(21)00592-4","article-title":"Isatuximab,\ncarfilzomib, and dexamethasone in relapsed\nmultiple myeloma (IKEMA): a multicentre, open-label, randomised phase\n3 trial","volume":"397","author":"Moreau","year":"2021","journal-title":"Lancet (London, England)"},{"key":"2026073102053715000_cit11","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1093\/rheumatology\/keu393","article-title":"Successful\ntreatment of warm-type\nhaemolytic anaemia with bortezomib in a rituximab-failed systemic\nlupus erythematosus patient","volume":"54","author":"Wang","year":"2015","journal-title":"Rheumatology (Oxford,\nEngland)"},{"key":"2026073102053715000_cit12","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1136\/annrheumdis-2014-206016","article-title":"The proteasome inhibitior bortezomib depletes plasma\ncells and ameliorates clinical manifestations of refractory systemic\nlupus erythematosus","volume":"74","author":"Alexander","year":"2015","journal-title":"Ann. Rheum. Dis."},{"key":"2026073102053715000_cit13","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1177\/0961203316686703","article-title":"The short-term\nefficacy of bortezomib combined with\nglucocorticoids for the treatment of refractory lupus nephritis","volume":"26","author":"Zhang","year":"2017","journal-title":"Lupus."},{"key":"2026073102053715000_cit14","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1080\/14397595.2018.1432331","article-title":"Multicenter double-blind randomized controlled trial\nto evaluate the effectiveness and safety of bortezomib as a treatment\nfor refractory systemic lupus erythematosus","volume":"28","author":"Ishii","year":"2018","journal-title":"Mod. Rheumatol."},{"key":"2026073102053715000_cit15","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1016\/S1470-2045(17)30578-8","article-title":"Carfilzomib\nor bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR):\nan interim overall survival analysis of an open-label, randomised,\nphase 3 trial","volume":"18","author":"Dimopoulos","year":"2017","journal-title":"Lancet Oncol."},{"key":"2026073102053715000_cit16","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/j.cell.2011.12.030","article-title":"Immuno- and constitutive\nproteasome crystal structures reveal differences in substrate and\ninhibitor specificity","volume":"148","author":"Huber","year":"2012","journal-title":"Cell"},{"key":"2026073102053715000_cit17","doi-asserted-by":"publisher","first-page":"2923","DOI":"10.2174\/156802611798281348","article-title":"The immunoproteasome:\nan emerging therapeutic target","volume":"11","author":"Lee","year":"2011","journal-title":"Curr. Top. Med.\nChem."},{"key":"2026073102053715000_cit18","doi-asserted-by":"publisher","first-page":"7032","DOI":"10.1021\/acs.jmedchem.9b00509","article-title":"Design and\nEvaluation\nof Highly Selective Human Immunoproteasome Inhibitors Reveal a Compensatory\nProcess That Preserves Immune Cell Viability","volume":"62","author":"Ladi","year":"2019","journal-title":"J. Med. Chem."},{"key":"2026073102053715000_cit19","doi-asserted-by":"publisher","first-page":"10230","DOI":"10.1021\/acs.jmedchem.1c00604","article-title":"Structure-Based\nOptimization and\nDiscovery of M3258, a Specific Inhibitor of the Immunoproteasome Subunit\nLMP7 (\u03b25i)","volume":"64","author":"Klein","year":"2021","journal-title":"J. Med. Chem."},{"key":"2026073102053715000_cit20","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.603278","article-title":"Co-Inhibition\nof the\nImmunoproteasome Subunits LMP2 and LMP7 Ameliorates Immune Thrombocytopenia","volume":"11","author":"Du","year":"2020","journal-title":"Front. Immunol."},{"key":"2026073102053715000_cit21","doi-asserted-by":"publisher","first-page":"11127","DOI":"10.1021\/acs.jmedchem.8b01201","article-title":"Required\nImmunoproteasome Subunit Inhibition Profile for Anti-Inflammatory\nEfficacy and Clinical Candidate KZR-616 ((2S,3R)-N-((S)-3-(Cyclopent-1-en-1-yl)-1-((R)-2-methyloxiran-2-yl)-1-oxopropan-2-yl)-3-hydroxy-3-(4-methoxyphenyl)-2-((S)-2-(2-morpholinoacetamido)propanamido)propenamide)","volume":"61","author":"Johnson","year":"2018","journal-title":"J. Med. Chem."},{"key":"2026073102053715000_cit22","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1043680","article-title":"Zetomipzomib (KZR-616) attenuates\nlupus in mice via\nmodulation of innate and adaptive immune responses","volume":"14","author":"Muchamuel","year":"2023","journal-title":"Front. Immunol."}],"container-title":["Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pubs.acs.org\/doi\/pdf\/10.1021\/acs.jmedchem.5c02583","content-type":"application\/pdf","content-version":"vor","intended-application":"unspecified"},{"URL":"https:\/\/pubs.acs.org\/jmcmar\/article-pdf\/68\/22\/24579\/66293849\/acs.jmedchem.5c02583.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/pubs.acs.org\/jmcmar\/article-pdf\/68\/22\/24579\/66293849\/acs.jmedchem.5c02583.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T06:05:44Z","timestamp":1785477944000},"score":1,"resource":{"primary":{"URL":"https:\/\/pubs.acs.org\/jmcmar\/article\/68\/22\/24579\/5234734\/Discovery-of-Novel-Potent-and-Safe"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,10]]},"references-count":22,"journal-issue":{"issue":"22","published-online":{"date-parts":[[2025,11,10]]},"published-print":{"date-parts":[[2025,11,27]]}},"URL":"https:\/\/doi.org\/10.1021\/acs.jmedchem.5c02583","relation":{"has-part":[{"id-type":"doi","id":"https:\/\/doi.org\/10.1021\/acs.jmedchem.5c02583.s001","asserted-by":"subject"},{"id-type":"doi","id":"https:\/\/doi.org\/10.1021\/acs.jmedchem.5c02583.s002","asserted-by":"subject"}]},"ISSN":["0022-2623","1520-4804"],"issn-type":[{"value":"0022-2623","type":"print"},{"value":"1520-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,10]]}}}